Clinical Trials Logo

Richter's Transformation clinical trials

View clinical trials related to Richter's Transformation.

Filter by:

NCT ID: NCT02138786 Terminated - Clinical trials for Richter's Transformation

Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation

SIRRT
Start date: November 14, 2014
Phase: Phase 2
Study type: Interventional

This is a multi-center, phase 2, single arm, open-label study of oral selinexor monotherapy in patients with Richter's Transformation, arising in the setting of prior chronic lymphocytic leukemia (CLL), after at least one chemo-immunotherapy regimen for CLL.

NCT ID: NCT01217749 Completed - Clinical trials for Small Lymphocytic Lymphoma

Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL

PCYC-1109-CA
Start date: December 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of a fixed-dose, daily regimen of orally administered PCI-32765 combined with ofatumumab in subjects with relapsed/refractory CLL/SLL and related diseases

NCT ID: NCT00472849 Completed - Leukemia Clinical Trials

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

Start date: May 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical research study is to find the highest tolerable dose of fludarabine and cytarabine that can be given in combination with oxaliplatin and rituximab in the treatment of chronic lymphocytic leukemia (CLL), prolymphocytic leukemia, or Richter's transformation. Once the highest tolerable dose for this drug combination is found, the next goal of the study will be to find out if this combination therapy is effective in shrinking or slowing the growth of these diseases.